Abstract 5615: ALRN-0192519 is a potent and selective EGFR L858R mutation inhibitor that demonstrates anti-cancer activity in preclinical cancer models as monotherapy or in combination with osimertinibJiaqi Liang, Lina Gu, Lisha Xie et al.|Cancer Research|2025Cited by 0